NCI-H460 Transfection Reagent (Lung Carcinoma, HTB177)

Altogen Biosystems is a recognized developer and laboratory for biological laboratories. Custom research offers and additional preclinical items include xenografts, toxicology assays, 28-day generation of stably-transfected cells, liposome encapsulation and more. Dedicated to assisting pharmaceutical companies with cutting-edge and excellent services, Altogen Biosystems endeavors to optimize modern laboratory technologies. Visit Altogen’s website for a list of lung xenograft models .

Derived nearly 40 years ago, the NCI-H460 cell line has a few unique characteristics that have made it one of the principal cell lines used in lung cancer research. NCI-H460 cells do not have significant damage to DNA, and they express normal amounts of p53 mRNA, making their proliferation somewhat of a mystery and a path towards discovering complex cell proliferation and tumorigenesis pathways. In terms of gene therapies to combat late-stage lung cancer, transfection reagents that are not cytotoxic can show how the large-cell carcinoma that is the NCI-H460 cell line responds to changes in its genome, possibly discovering novel manners of curing lung cancer even after late diagnosis.